WO1996013226A1 - Methode de traitement de la periodontite et composition pharmaceutique utilisee dans le cadre de cette methode - Google Patents
Methode de traitement de la periodontite et composition pharmaceutique utilisee dans le cadre de cette methode Download PDFInfo
- Publication number
- WO1996013226A1 WO1996013226A1 PCT/US1995/013989 US9513989W WO9613226A1 WO 1996013226 A1 WO1996013226 A1 WO 1996013226A1 US 9513989 W US9513989 W US 9513989W WO 9613226 A1 WO9613226 A1 WO 9613226A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- growth factor
- nsaid
- dental tissue
- pharmaceutically acceptable
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 48
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 42
- 208000028169 periodontal disease Diseases 0.000 title claims description 22
- 239000003102 growth factor Substances 0.000 claims abstract description 45
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims abstract description 42
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims abstract description 42
- 229920001184 polypeptide Polymers 0.000 claims abstract description 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 27
- 201000001245 periodontitis Diseases 0.000 claims abstract description 17
- 241000124008 Mammalia Species 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims description 19
- 238000009472 formulation Methods 0.000 claims description 11
- 239000000606 toothpaste Substances 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 230000001172 regenerating effect Effects 0.000 claims description 7
- 229940034610 toothpaste Drugs 0.000 claims description 7
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 6
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 6
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 6
- -1 aryl propionic acids Chemical class 0.000 claims description 6
- 239000002324 mouth wash Substances 0.000 claims description 6
- 229960002390 flurbiprofen Drugs 0.000 claims description 5
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 5
- 229940051866 mouthwash Drugs 0.000 claims description 5
- 235000019260 propionic acid Nutrition 0.000 claims description 4
- 238000011200 topical administration Methods 0.000 claims description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 3
- 229960000991 ketoprofen Drugs 0.000 claims description 3
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims description 3
- 229960004752 ketorolac Drugs 0.000 claims description 3
- 229960005489 paracetamol Drugs 0.000 claims description 3
- 230000003449 preventive effect Effects 0.000 claims description 3
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 claims description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 2
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 claims description 2
- 229960003184 carprofen Drugs 0.000 claims description 2
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229960005293 etodolac Drugs 0.000 claims description 2
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 claims description 2
- 229960001680 ibuprofen Drugs 0.000 claims description 2
- 229960004187 indoprofen Drugs 0.000 claims description 2
- JVGUNCHERKJFCM-UHFFFAOYSA-N mabuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(=O)NCCO)C=C1 JVGUNCHERKJFCM-UHFFFAOYSA-N 0.000 claims description 2
- 229950001846 mabuprofen Drugs 0.000 claims description 2
- 229960002009 naproxen Drugs 0.000 claims description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 2
- 229960003101 pranoprofen Drugs 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 24
- 208000007565 gingivitis Diseases 0.000 description 8
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 5
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 4
- 230000001066 destructive effect Effects 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000004195 gingiva Anatomy 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 208000002679 Alveolar Bone Loss Diseases 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000019884 chronic gingivitis Diseases 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
- SYTBZMRGLBWNTM-JTQLQIEISA-N (S)-flurbiprofen Chemical compound FC1=CC([C@@H](C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-JTQLQIEISA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- DKYWVDODHFEZIM-NSHDSACASA-N dexketoprofen Chemical compound OC(=O)[C@@H](C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-NSHDSACASA-N 0.000 description 1
- 229960002783 dexketoprofen Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
Definitions
- the present invention relates generally to the treatment of periodontal disease and more particularly to a novel method for treating periodontal disease and to a pharmaceutical composition useful in said method.
- Periodontal disease which includes any abnormality, whether inflammatory or degenerative, of tissue around a tooth, is very common worldwide.
- the World Health Organization estimated some years ago that, even if there were no new periodontal disease, it would still take 45 years to treat those people already afflicted therewith.
- the Journal of Public Health Dentistry concluded in 1985 that "more than two out of three patients were affected by periodontal disease.” Moos, W.F., Medical Marketing & Media, 52-54 (1985).
- Periodontal disease Two common types of periodontal disease are chronic gingivitis (i.e., an inflammation of the gingiva or gums) and chronic destructive periodontitis (i.e., a disease of the connective tissue which attaches a tooth to the alveolar bone, which disease results in alveolar bone resorption, increasing mobility of the tooth and, ultimately, tooth loss).
- chronic gingivitis hereinafter simply “gingivitis”
- chronic destructive periodontitis hereinafter simply “periodontitis” actually represent varying stages of periodontal disease, with gingivitis, if uncontrolled, progressing into periodontitis.
- periodontal disease is caused, at least initially, by the accumulation of bacterial plaque on the teeth and under the gingiva of a patient, said accumulation of plaque triggering an inflammatory and immunological response in the patient.
- Preventive techniques have relied heavily on establishing and maintaining good oral hygiene including mechanically and/or chemically preventing the accumulation of bacterial plaque on the teeth and under the gingiva.
- Therapies directed at treating existing advanced periodontal disease have primarily been directed at expensive and ongoing medical procedures, such as periodontal surgery, which in many cases must be carried out often over an indefinite period of time and which have not been clearly shown to be effective in arresting alveolar bone loss and preserving teeth. Because of the initial inflammatory aspect of periodontal disease, a number of researchers have recently investigated the use of certain anti- inflammatory agents as possible therapies for treating gingivitis.
- the method comprises applying to buccal membranes a therapeutically effective quantity of an enantiomer, generally an S enantiomer, of a nonsteroidal anti-inflammatory drug, such as (S)- flurbiprofen or (S)-ketoprofen.
- an enantiomer generally an S enantiomer
- a nonsteroidal anti-inflammatory drug such as (S)- flurbiprofen or (S)-ketoprofen.
- the composition is a formulation which is a toothpaste or which is a mouthwash.
- a method for regenerating mammalian dental tissue such as that afflicted with periodontitis (e.g., gum tissue, periodontal ligature, etc.) comprising the step of administering to the mammalian dental tissue a therapeutically effective amount of a pharmaceutical composition comprising a growth factor and an NSAID.
- a pharmaceutical composition comprising a growth factor and an NSAID.
- the growth factor of the present pharmaceutical composition is a polypeptide (i.e., proteinaceous) growth factor.
- polypeptide growth factor refers to a class of natural biological mediators that regulate the proliferation, differentiation, motility and matrix synthesis of nearly all cell types. It is also believed that such factors play important roles in soft and hard tissue repair.
- polypeptide growth factors include, but are not limited to, platelet-derived growth factor (PDGF), insulin-like growth factor-1 (IGF-1 ), transforming growth factor alpha (TGF- ⁇ ), cartilage-derived growth factor (CDGF) and growth hormones (such as human growth hormone).
- polypeptide growth factors of the present invention may be naturally occurring polypeptide growth factors, polypeptide growth factors obtained by recombinant means expressed in either eukaryotic or prokaryotic systems, biologically active mutant forms of naturally occurring polypeptide growth factors, biologically active fragments or subunits of naturally occurring polypeptide growth factors, or biologically active mutants of biologically active fragments or subunits of naturally occurring polypeptide growth factors.
- NSAID as used in the present specification and claims, is defined to mean a non-steroidal, anti-inflammatory drug and is to be contrasted with steroidal, anti-inflammatory drugs.
- NSAID's include, but are not limited to acetaminophen, ketorolac, aspirin and the class of aryl propionic acids, such as ketoprofen, etodolac, flurbiprofen, carprofen, ibuprofen, naproxen, indoprofen, pierprofen, pranoprofen, microprofen, thiaoxa and aminoprofen.
- the NSAID is preferably in the form of a substantially pure, pharmacologically active enantiomer.
- the pharmacologically active enantiomer is the S(+) enantiomer.
- a method of regenerating mammalian dental tissue afflicted with periodontitis and, over a subsequent period of time, preventing the resorption of the regenerated mammalian dental tissue comprising the steps of (a) administering to the afflicted mammalian dental tissue a therapeutically effective amount of a pharmaceutical composition comprising an NSAID and a growth factor, for example, a polypeptide growth factor; and (b) then, administering to the regenerated mammalian dental tissue a therapeutically effective amount of an NSAID to prevent the resorption of the regenerated mammalian dental tissue over said subsequent period of time.
- the present invention is also directed to a pharmaceutical composition useful in regenerating mammalian dental tissue, such as that afflicted with periodontitis, the pharmaceutical composition comprising an NSAID and a growth factor, for example, a polypeptide growth factor.
- the aforementioned pharmaceutical composition is also useful in reducing inflamed mammalian dental tissue, such as that afflicted with gingivitis.
- the present invention is directed at a new method of treating periodontitis and at a new pharmaceutical composition useful in said method (it being understood that the present method and pharmaceutical composition could also be used to treat gingivitis).
- the method of the present invention comprises the following steps: First, a pharmaceutical composition comprising a polypeptide growth factor and an NSAID is administered to a mammal suffering from periodontitis, the pharmaceutical composition being administered in a therapeutically effective amount to cause the regeneration and repair of afflicted dental tissue in the mammal. Then, an NSAID is administered to the afflicted mammal, the NSAID being administered in a therapeutically effective amount to prevent the repaired and regenerated dental tissue from thereafter being lost, for example, by alveolar bone resorption.
- the aforementioned first step will be performed by a dentist or similar dental care provider by directly applying to the affected dental tissue a composition of the polypeptide growth factor and the NSAID in a pharmaceutically acceptable carrier for topical administration.
- pharmaceutically acceptable carriers are ointments, creams, gels, matrices and liquids of the type described in U.S. Patent No. 5,149,691.
- combinations of the aforementioned polypeptide growth factors such as PDGF+IGF-1 or PDGF+TGF ⁇ , may be used instead of a single polypeptide growth factor to achieve greater healing of the injured tissue.
- combinations of NSAID's may be used instead of a single NSAID.
- the NSAID is chiral, it is preferable to include only the pharmacologically active enantiomer, which is typically the S(+) enantiomer.
- Flavoring or buffering agents may additionally be included in the above-described pharmaceutical composition to counter the unpleasant effects associated with the topical administration of NSAID's.
- the range of concentration for the polypeptide growth factor in the subject pharmaceutical composition can be approximately 10 mg/ml to 1 g/ml, and the range of concentration for the NSAID in the subject pharmaceutical composition can be approximately 50 mg/ml to 50 g/ml.
- the aforementioned second step of preserving the repaired and regenerated dental tissue will be performed by the patient by directly applying to the affected dental tissue a composition of an NSAID in a pharmaceutically acceptable formulation.
- pharmaceutically acceptable formulations are toothpastes and mouthwashes of the type described in U.S. Patent No. 5,190,981 , as well as gels of the type typically applied using a dental impression-type tray.
- suitable compositions comprising an NSAID in a toothpaste or mouthwash formulation are also described in U.S. Patent No. 5,190,981.
- Such compositions preferably also include a cavity preventive agent, as well as a flavoring or buffering agent.
- the NSAID-containing toothpaste or mouthwash will be administered by the patient twice daily over an indefinite period of time, i.e., the lifetime of the patient. Long-term use of the NSAID-containing toothpaste or mouthwash is presently deemed to be advisable to prevent the subsequent resorption of the newly regenerated dental tissue.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'invention concerne une méthode de traitement de la périodontite et une composition pharmaceutique utilisée dans le cadre de cette méthode. Selon le mode de réalisation préféré, la méthode consiste à administrer à un mammifère atteint d'une périodontite une dose efficace sur le plan thérapeutique d'une composition pharmaceutique comprenant un facteur de croissance de polypeptide ainsi qu'un anti-inflammatoire non stéroïdien pour régénérer le tissu dentaire du mammifère malade et, par la suite, à lui administrer une dose efficace sur le plan thérapeutique d'un anti-inflammatoire non stéroïdien pour empêcher la résorption du tissu dentaire nouvellement régénéré.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU41375/96A AU4137596A (en) | 1994-10-31 | 1995-10-30 | Method for the treatment of periodontal disease and a pharmaceutical composition useful in said method |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33253294A | 1994-10-31 | 1994-10-31 | |
| US08/332,532 | 1994-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1996013226A1 true WO1996013226A1 (fr) | 1996-05-09 |
Family
ID=23298643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1995/013989 WO1996013226A1 (fr) | 1994-10-31 | 1995-10-30 | Methode de traitement de la periodontite et composition pharmaceutique utilisee dans le cadre de cette methode |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU4137596A (fr) |
| WO (1) | WO1996013226A1 (fr) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0821970A1 (fr) * | 1996-08-02 | 1998-02-04 | Edward Henri Charles Verhaeren | Véhicule pour moduler la perméabilité de la jonction étanche |
| EP2322226A3 (fr) * | 1999-07-21 | 2011-08-17 | Omeros Corporation | Solutions et procédés pour l'inhibition de la douleur, la inflammation et la degradation du cartilage |
| US8870954B2 (en) | 2008-09-09 | 2014-10-28 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries |
| US9161967B2 (en) | 2006-06-30 | 2015-10-20 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
| US9545377B2 (en) | 2004-10-14 | 2017-01-17 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods of use thereof |
| US9642891B2 (en) | 2006-06-30 | 2017-05-09 | Biomimetic Therapeutics, Llc | Compositions and methods for treating rotator cuff injuries |
| US10258566B2 (en) | 2004-10-14 | 2019-04-16 | Biomimetic Therapeutics, Llc | Compositions and methods for treating bone |
| US11235030B2 (en) | 2010-02-22 | 2022-02-01 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods for the treatment of tendinopathies |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4919939A (en) * | 1986-04-29 | 1990-04-24 | Pharmetrix Corporation | Periodontal disease treatment system |
| US5324519A (en) * | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| US5447725A (en) * | 1993-06-11 | 1995-09-05 | The Procter & Gamble Company | Methods for aiding periodontal tissue regeneration |
-
1995
- 1995-10-30 WO PCT/US1995/013989 patent/WO1996013226A1/fr active Application Filing
- 1995-10-30 AU AU41375/96A patent/AU4137596A/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4919939A (en) * | 1986-04-29 | 1990-04-24 | Pharmetrix Corporation | Periodontal disease treatment system |
| US5324519A (en) * | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| US5447725A (en) * | 1993-06-11 | 1995-09-05 | The Procter & Gamble Company | Methods for aiding periodontal tissue regeneration |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0821970A1 (fr) * | 1996-08-02 | 1998-02-04 | Edward Henri Charles Verhaeren | Véhicule pour moduler la perméabilité de la jonction étanche |
| WO1998005359A1 (fr) * | 1996-08-02 | 1998-02-12 | Ghyssaert, Joris, Rosa, Michael | Composition de transport destinee a influencer la permeabilite des jonctions serrees |
| EP2322226A3 (fr) * | 1999-07-21 | 2011-08-17 | Omeros Corporation | Solutions et procédés pour l'inhibition de la douleur, la inflammation et la degradation du cartilage |
| US11571497B2 (en) | 2004-10-14 | 2023-02-07 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods of use thereof |
| US11364325B2 (en) | 2004-10-14 | 2022-06-21 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods of use thereof |
| US9545377B2 (en) | 2004-10-14 | 2017-01-17 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods of use thereof |
| US11318230B2 (en) | 2004-10-14 | 2022-05-03 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods of use thereof |
| US10258566B2 (en) | 2004-10-14 | 2019-04-16 | Biomimetic Therapeutics, Llc | Compositions and methods for treating bone |
| US11058801B2 (en) | 2006-06-30 | 2021-07-13 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
| US10456450B2 (en) | 2006-06-30 | 2019-10-29 | Biomimetic Therapeutics, Llc | Compositions and methods for treating rotator cuff injuries |
| US9642891B2 (en) | 2006-06-30 | 2017-05-09 | Biomimetic Therapeutics, Llc | Compositions and methods for treating rotator cuff injuries |
| US9161967B2 (en) | 2006-06-30 | 2015-10-20 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
| US11135341B2 (en) | 2008-09-09 | 2021-10-05 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor composition and methods for the treatment of tendon and ligament injuries |
| US8870954B2 (en) | 2008-09-09 | 2014-10-28 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries |
| US11235030B2 (en) | 2010-02-22 | 2022-02-01 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods for the treatment of tendinopathies |
Also Published As
| Publication number | Publication date |
|---|---|
| AU4137596A (en) | 1996-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5902110A (en) | Bone regeneration | |
| US5939047A (en) | Local delivery of chemotherapeutic agents for treatment of periodontal disease | |
| EP0137668B2 (fr) | Ibuprofen, flurbiprofen et leur utilisation en thérapeutique | |
| US4097604A (en) | Method of treating and controlling gingivitis | |
| Hirooka | The biologic concept for the use of enamel matrix protein: true periodontal regeneration. | |
| Henry et al. | Tissue regeneration in bony defects adjacent to immediately loaded titanium implants placed into extraction sockets: a study in dogs. | |
| US4215144A (en) | Method of treating and controlling gingivitis | |
| Rasperini et al. | The soft tissue wall technique for the regenerative treatment of non-contained infrabony defects: a case series | |
| US4214006A (en) | Mouthwash and method for preventing and removing dental plaque | |
| Castioni et al. | Current status in oral fluoride pharmacokinetics and implications for the prophylaxis against dental caries | |
| WO1996013226A1 (fr) | Methode de traitement de la periodontite et composition pharmaceutique utilisee dans le cadre de cette methode | |
| GINGIVITIS | Treatment of plaque-induced gingivitis, chronic periodontitis, and other clinical conditions | |
| Eeckhout et al. | A randomized controlled trial evaluating hyaluronic acid gel as wound healing agent in alveolar ridge preservation | |
| EP0486561B2 (fr) | Composition pour la bouche contenant du s(+) ketoprofene | |
| US4985235A (en) | Treatment of periodontoclasia with retinoic acid | |
| Taib et al. | Amlodipine-induced gingival overgrowth: a case report | |
| EP3914258B1 (fr) | Composition pour le traitement de la parodontite et la régénération de la papille interdentaire | |
| JPH0645535B2 (ja) | 歯槽骨代謝治療用組成物 | |
| EP0266354B1 (fr) | Composition pour preparer un medicament destine au traitement topique des affections du paradentium | |
| Farahmand et al. | Clinical evaluation of topical application of Doxycycline 3%+ Ketoprofen 2.5% Gel in chronic periodontitis patients | |
| AU614643B2 (en) | Treatment of periodontoclasia with retinoic acid | |
| JPH09291018A (ja) | 口腔用組成物 | |
| Chee | Peri-implant management of patients with aggressive periodontitis | |
| Wijaksana et al. | Fibrin-assisted soft tissue promotion (FASTP) as a simple root coverage technique: A case report | |
| Kurien et al. | The pouch and tunnel technique for the management of adjacent gingival recession defects: surgical correction and one-year follow-up |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase |